Looking to expand its biosimilar market coverage, Amgen has formed an exclusive co-development agreement with Chinese drug manufacturer, Simcere Pharmaceutical.
The goal of the agreement is to bring four undisclosed oncology and inflammation biosimilars in Amgen’s portfolio to commercialization in China.
Amgen will produce and submit approval applications for the drugs, while Simcere will handle Chinese distribution and commercialization.
Read the press release
